Reduction of Tumor Burden, Promotion of Hepatic Progenitor-Cell Differentiation, and Induction of Antitumor Immunity in Intrahepatic CCA with Ivosidenib, a Selective IDH1 Inhibitor

2020 Year in Review: Cholangiocarcinoma — December 19, 2020

Preclinical evidence using an genetically engineered mouse model of IDH1-mutated intrahepatic CCA indicates that the selective IDH1 inhibitor ivosidenib mediates its antitumor activity by promoting hepatic progenitor-cell differentiation, and inducing T-cell–mediated antitumor immune response.

Among the most common genetic alterations in intrahepatic CCA are mutations in the isocitrate dehydrogenase (IDH)1 and IDH2 enzymes. These mutations are present in approximately 20% of patients. IDH proteins are enzymes involved in diverse cellular processes, including histone demethylation and DNA modification. A critical component of the tricarboxylic acid (ie, citric acid or Krebs) cycle is the IDH2 protein, which is localized in the mitochondria.

The mutated IDH protein exhibits aberrant enzymatic function, reducing alpha-ketoglutarate (αKG, which plays a critical role in the metabolism of cellular energy) to the oncometabolite 2-hydroxyglutarate (2-HG). The 2-HG competitively inhibits αKG-dependent histone and DNA demethylating enzymes, thereby altering the regulation of chromatin, which plays a crucial role in regulating gene expression.

In phase 1 and 2 clinical trials of patients with intrahepatic CCA and IDH1 mutation, the first-in-class small-molecule ivosidenib (Tibsovo), a selective IDH1 inhibitor, has shown benefit. Data from the 2 clinical trials were so convincing that the National Comprehensive Cancer Network (NCCN) added ivosidenib to its updated guidelines of hepatobiliary cancers published on June 1, 2020.

According to the NCCN Drugs & Biologics Compendium specific recommendation, the drug is approved for “Subsequent treatment as a single-agent…for progression on or after systemic treatment for unresectable or metastatic disease with an isocitrate dehydrogenase-1 (IDH1) mutation.”

Meng-Ju Wu, PhD, MS, Postdoctoral Research Fellow, Center for Cancer Research, Massachusetts General Hospital, Boston, and colleagues explored the relationship between treatment with ivosidenib and the vehicle therapy, and the mechanism underlying the response to the inhibition of IDH1, using a proprietary, first genetically engineered mouse model of intrahepatic CCA with IDH1 mutation. Results were presented by Dr Wu at an oral presentation during this year’s annual meeting of the American Association for Cancer Research (AACR).

Along with reducing the overall tumor burden—a reduction of tumor-produced 2-HG >85% was also observed—ivosidenib was discovered to promote hepatocyte-cell differentiation (2-HG hinders hepatic progenitor-cell differentiation) to mature hepatocytes.

In addition, Dr Wu and colleagues detected an enhanced immune response to ivosidenib in this mouse model. They noted an increased recruitment of CD8-positive T-cells to the tumors. This increase is important because the tumor microenvironment in intrahepatic CCA dampens the activity of CD8-positive T-cells and other immune cells, such as natural killer cells and dendritic cells. Pronounced induction of immune stimulatory interferon signaling was noted, and PD-L1 expression was upregulated.

Dr Wu concluded at the AACR meeting, “My study provides the first faithful genetically engineered mouse model of IDH1-mutated intrahepatic cholangiocarcinoma. It will elucidate the tumor maintenance program driven by IDH1 mutation, defining the impact of this oncogene on tumor-cell epigenetic programs and tumor-immune microenvironment interplay. The work provides a strong preclinical rationale for combination treatment strategies involving ivosidenib in patients with intrahepatic cholangiocarcinoma and IDH1 mutation.”

Source: Wu MJ, et al. Cancer Res. 2020;80(16_suppl). Abstract 1810.

Related Items

KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review: Cholangiocarcinoma
In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer.
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
2023 Year in Review: Cholangiocarcinoma
This post-hoc analysis of the ABC-01, -02, and -03 clinical trials provides reference survival data for patients with advanced extrahepatic cholangiocarcinoma treated with first-line gemcitabine/cisplatin chemotherapy.
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
2023 Year in Review: Cholangiocarcinoma
Investigators pooled data from 3 trials to evaluate tinengotinib in patients with advanced, refractory/relapsed cholangiocarcinoma who previously received an FGFR inhibitor.
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
2023 Year in Review: Cholangiocarcinoma
Researchers evaluated KLF5 expression and its inhibition in cholangiocarcinoma using clustered regularly interspaced short palindromic repeats technology.
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
2023 Year in Review: Cholangiocarcinoma
In this ongoing phase 2 study, the efficacy of SHR-1316 plus IBI310 is being evaluated in patients with advanced intrahepatic cholangiocarcinoma after inadequate response to first-line therapy.
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
2023 Year in Review: Cholangiocarcinoma
Dr Mahmood presented results from the largest multi-institutional review of efficacy outcomes following targeted agents in patients with cholangiocarcinoma.
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
2023 Year in Review: Cholangiocarcinoma
In the phase 2 component of the phase 2/3 BEER-BTC study, bevacizumab plus erlotinib improved outcomes in patients with advanced biliary tract cancers.
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
2023 Year in Review: Cholangiocarcinoma
Researchers investigated the efficacy and safety of neoadjuvant durvalumab plus gemcitabine/cisplatin (GemCis) versus GemCis alone in patients with biliary tract cancer.
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
2023 Year in Review: Cholangiocarcinoma
In the ongoing phase 2 ADJUBIL study, the clinical activity of immunotherapies durvalumab and tremelimumab with or without capecitabine is being assessed in patients with resectable biliary tract cancer in the adjuvant setting.
Tucatinib and Trastuzumab in Patients With Previously Treated HER2-Positive Metastatic BTC: The SGNTUC-019 Study
2023 Year in Review: Cholangiocarcinoma
This phase 2 basket study investigated the combination of tucatinib and trastuzumab as second-line treatment for patients with HER2-positive biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: